AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31034251
Drug: C-W (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-W (daily consumption of control margarine with 30-min daily walking)
Trial: 28544241
Drug: RRR-α-tocopherol supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-α-tocopherol supplementation (400 IU single dose)
Trial: 23937010
Drug: Myrtol Standardized
RxNorm normalized name: myrtol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrtol Standardized Enteric Coated Soft Capsules, 0.3 g, 3 times a day, for 3 months
Trial: 23937010
Drug: Myrtol Standardized
RxNorm normalized name: myrtol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrtol Standardized Enteric Coated Soft Capsules
Trial: 17031646
Drug: CP‐547,632 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐547,632 plus paclitaxel (225 mg/m²) and carboplatin (AUC = 6) every 3 weeks
Trial: 17031646
Drug: CP‐547,632 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP‐547,632 plus chemotherapy
Trial: 14615471
Drug: BIA 3-202
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIA 3-202 (50 mg, 100 mg, 200 mg twice daily and 200 mg thrice daily)
Trial: 10754780
Drug: E2 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 supplementation (2 mg two times daily) from the early proliferative phase to the late secretory phase of the endometrium
Trial: 10754780
Drug: E2 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 supplementation (2 mg two times daily)
Trial: 3872835
Drug: Nicardipine (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine (7.5 mg)
Trial: 3872835
Drug: Verapamil (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (16 mg)
Trial: 28961380
Drug: Active treatment
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment (magnetic stimulation)
Trial: 26100611
Drug: HORIZON trauma
RxNorm normalized name: Horizant
DrugBank: Gabapentin enacarbil (DB08872)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HORIZON trauma focused cognitive behavioral therapy with parental components
Trial: 15136099
Drug: Endometrial sampling
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial sampling and measurement of serum estradiol and progesterone 1 to 14 days after the midcycle urinary luteinizing hormone surge.
Trial: 11841079
Drug: Gastrografin 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gastrografin 200 ml orally for 2 consecutive days before operation
Trial: 11841079
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution through a nasogastric tube
Trial: 10463377
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg physostigmine patch
Trial: 10463377
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg physostigmine patch
Trial: 7595767
Drug: Neonatal amino
RxNorm normalized name: Foreskin fibroblast (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neonatal amino acid formulation
Trial: 7595767
Drug: General-purpose intravenous
RxNorm normalized name: Corona Multi-Purpose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General-purpose intravenous amino acid solution
Trial: 28202013
Drug: Clarithromycin-based sequential
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin-based sequential treatment (10-day regimen: Proton-Pump Inhibitor + Amoxicillin 1 g bid for 5 days and Proton-Pump Inhibitor + Clarithromycin 500 mg + Metronidazole/Tinidazole 500 mg bid/tid for the following 5 days)
Trial: 28202013
Drug: Levofloxacin-based sequential
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin-based sequential treatment (10-day modified regimen with Levofloxacin 500 mg id instead of Clarithromycin)
Trial: 22799528
Drug: Extraction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extraction treatment (Group 1)
Trial: 22799528
Drug: Nonextraction treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonextraction treatment (Group 2)
Trial: 21492764
Drug: Rosuvastatin 20
RxNorm normalized name: rosuvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 20 mg daily (without LDL-C <50 mg/dl)
Trial: 8889317
Drug: Propranolol (PRO)
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (PRO) 80 mg x 2/day for 7 days
Trial: 8889317
Drug: Pindolol (PIN)
RxNorm normalized name: Pindolol
DrugBank: Pindolol (DB00960)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pindolol (PIN) 10 mg x 2/day for 7 days
Trial: 1824585
Drug: Ephedrine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ephedrine (0.5 mg/kg)
Trial: 1824585
Drug: Droperidol (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (0.04 mg/kg)
Trial: 6407438
Drug: Diltiazem 240
RxNorm normalized name: diltiazem 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem 240 or 360 mg/day
Trial: 2883817
Drug: temazepam (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: temazepam (20 mg/day)
Trial: 2883817
Drug: flunitrazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunitrazepam (2 mg/day)
Trial: 29084042
Drug: Local drug
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local drug delivery of abciximab (IL, by the ClearWay catheter) plus aspiration thrombectomy (AT)
Trial: 29084042
Drug: Nonlocal drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonlocal drug delivery of abciximab (IC, by the guide catheter) plus aspiration thrombectomy (AT)
Trial: 26971071
Drug: Cognitive Behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavior Therapy for psychosis based Guided Self-help (CBTp-GSH)
Trial: 23906195
Drug: Age, use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Age, use of antiarrhythmic drugs, and AEMI
Trial: 22252094
Drug: pill placebo
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pill placebo (PLA‐CM)
Trial: 18322988
Drug: Somatic absorption
RxNorm normalized name: Bos taurus somatic nerve preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatic absorption
Trial: 16124422
Drug: 4 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg/day of artesunate for 3 days and 3 daily doses of 8.0 mg/kg/day mefloquine
Trial: 16124422
Drug: 4 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg/day of artesunate for 3 days and mefloquine given as 15 mg/kg on the first day and 10 mg/kg on the second day
Trial: 6342784
Drug: Fenbufen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenbufen (600 mg daily)
Trial: 30255637
Drug: Play activities
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Play activities program (1 hour weekly for 8 weeks)
Trial: 30255637
Drug: Reading books
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reading books and magazines (15 minutes weekly for 8 weeks)
Trial: 24878457
Drug: Interval appendectomy
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval appendectomy (4-6 weeks after initial treatment with antibiotics)
Trial: 18321181
Drug: Overall study
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall study population (n = 35 who initiated treatment)
Trial: 15557136
Drug: 500 ppm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ppm CO inhalation for 1 hour
Trial: 15557136
Drug: Synthetic air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic air (placebo) inhalation
Trial: 12218381
Drug: High-dose estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose estrogen plus methyltestosterone
Trial: 12218381
Drug: High-dose estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose estrogen
Trial: 10671963
Drug: 5% benzoyl
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 mL TOPICAL SOAP [Benzoyl Acne Wash -2.5% Benzoyl Peroxide]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% benzoyl peroxide cream
Trial: 8874253
Drug: 2 days
RxNorm normalized name: Chapstick 12 Days of Christmas KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 days of i.v. antibiotics followed by 8 days of oral therapy
Trial: 8874253
Drug: 5 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 days of i.v. antibiotics followed by 5 days of oral therapy
Trial: 8874253
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of i.v. antibiotics
Trial: 1686784
Drug: Lacidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4 mg once a day, at 0700 h)
Trial: 29882087
Drug: Riociguat 0.5
RxNorm normalized name: riociguat 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat 0.5 mg
Trial: 29882087
Drug: Riociguat 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat 1.0 mg
Trial: 29882087
Drug: Biperiden 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 2.0 mg
Trial: 29882087
Drug: Biperiden 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 2.0 mg and Riociguat 0.5 mg
Trial: 29882087
Drug: Biperiden 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biperiden 2.0 mg and Riociguat 1.0 mg
Trial: 29798272
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (radiotherapy)
Trial: 23075703
Drug: lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lopinavir/ritonavir (LPV/r) 400/100 mg twice daily monotherapy (mono‐LPV/r)
Trial: 23075703
Drug: tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tenofovir disoproxil fumarate (TDF) once daily plus lamivudine (3TC) twice daily plus LPV/r 400/100 mg twice daily (TDF/3TC/LPV/r)
Trial: 20574412
Drug: Quadrivalent human
RxNorm normalized name: PAPILLOMAVIRUS HUMAN QUADRIVALENT VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent human papillomavirus vaccine (QHPV)
Trial: 18664696
Drug: Cognitive-behavior therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavior therapy (CBT) package for social anxiety
Trial: 18664696
Drug: Speech restructuring
RxNorm normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speech restructuring treatment alone
Trial: 17057794
Drug: Mitomycin 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin 0.25 mg/mL for 1 minute combined with temporary nasal tarsorrhaphy
Trial: 12271112
Drug: Cognitive behavior
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavior therapy (CBT) self-help manual in six modules
Trial: 7792546
Drug: Multimodal cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cognitive-behavioural treatments (MMCBT) with psychologist as a coach (Group A)
Trial: 7792546
Drug: Multimodal cognitive-behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal cognitive-behavioural treatments (MMCBT) with direct psychologist contact (Group B)
Trial: 1706610
Drug: T-cell ML
RxNorm normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-cell ML
Trial: 1706610
Drug: B-cell ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B-cell ML
Trial: 19090439
Drug: Surgery, adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, adjuvant treatment, or radiotherapy
Trial: 14654574
Drug: Angiotensin-II antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-II antagonists
Trial: 9168214
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine (10 mg in 20 mL normal saline)
Trial: 9168214
Drug: Intra-articular bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular bupivacaine (20 mL 0.5% with epinephrine)
Trial: 9168214
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine (10 mg in 1 mL)
Trial: 9168214
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 mL IA normal saline + 1 mL SC normal saline)
Trial: 8063651
Drug: Isradipine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isradipine (5 mg/day; n = 6)
Trial: 2646850
Drug: Propofol (1.5-2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.5-2.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Trial: 2646850
Drug: Thiopentone (3.0-4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (3.0-4.0 mg/kg i.v. combined with diazepam 0.2 mg/kg i.v.)
Trial: 21273301
Drug: Early treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early treatment for Women with Alcohol Addiction (EWA)
Trial: 20387350
Drug: Pethidine (0.35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pethidine (0.35 mg/kg)
Trial: 20387350
Drug: Doxapram (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (1.5 mg/kg)
Trial: 11529248
Drug: phVEGF165 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: phVEGF165 gene transfer (1, 2, or 4 mg)
Trial: 7620002
Drug: Ceftazidime monotherapy
RxNorm normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ceftazidime monotherapy
Trial: 24974155
Drug: Prednisone 50
RxNorm normalized name: prednisone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 50 mg for 7 days
Trial: 25628082
Drug: Control -
RxNorm normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control - Edgewise therapy only
Trial: 17766699
Drug: Rituximab alone
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab alone (1000 mg administered intravenously on days 1 and 15)
Trial: 17766699
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus cyclophosphamide (750 mg administered intravenously on days 3 and 17)
Trial: 17766699
Drug: Methotrexate alone
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate alone (10-25 mg/wk)
Trial: 15077929
Drug: CYFRA 21-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYFRA 21-1 in F0 expressed in ng/mg TP
Trial: 15077929
Drug: NSE in
RxNorm normalized name: Good Sense Infants Pain Reliver
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSE in both fractions expressed in ng/mg TP
Trial: 15077929
Drug: SCC in
RxNorm normalized name: SCC
DrugBank: Sodium copper chlorophyllin (DB16522)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCC in F1 expressed in ng/mg TP
Trial: 15077929
Drug: TPA in
RxNorm normalized name: zinc-DTPA Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPA in F0 expressed in mU/mg TP
Trial: 15077929
Drug: TPS in
RxNorm normalized name: OTX-TP
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: TPS in both fractions expressed in mU/mg TP
Trial: 11229833
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg oral vitamin K1
Trial: 11229833
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of one dose of acenocoumarine
Trial: 2091170
Drug: Concurrent visual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent visual feedback during abduction of the fifth digit
Trial: 674355
Drug: Long acting
RxNorm normalized name: Long Acting Nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long acting neuroleptic drugs (fluphenazine decanoate, flupenthixol decanoate, fluspirilene)
Trial: 30795731
Drug: Tiotropium (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (5 µg and 2.5 µg)
Trial: 20939064
Drug: Placebo compliance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo compliance (high compliance defined as taking 80% or more of dispensed study medication)
Trial: 19335707
Drug: AZD6140 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 90 mg twice daily
Trial: 19335707
Drug: AZD6140 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD6140 180 mg twice daily
Trial: 16710253
Drug: Spirapril (stepwise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spirapril (stepwise antihypertensive therapy)
Trial: 16710253
Drug: Hypotensive drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypotensive drugs (standard treatment)
Trial: 7955818
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg mofegiline
Trial: 7955818
Drug: 12 mg
RxNorm normalized name: pectin 12 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg mofegiline
Trial: 7955818
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg mofegiline
Trial: 29504258
Drug: Low-dose rhEPO
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rhEPO for 2 weeks
Trial: 29504258
Drug: High-dose rhEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose rhEPO for 3 days
Trial: 8823102
Drug: Heparin-coated surfaces
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated surfaces
Trial: 8823102
Drug: Roller pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roller pump (heparin-coated circuits)
Trial: 1878235
Drug: bupivacaine 0.5%
RxNorm normalized name: BUPivacaine 0.5% injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bupivacaine 0.5% with fentanyl 50 micrograms in 10 ml of saline (Group 3, n = 15)
Trial: 31827320
Drug: Esketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esketamine (0.5 mg/kg)
Trial: 31827320
Drug: Racemic ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racemic ketamine (1 mg/kg)
Trial: 25683315
Drug: Botulinum Toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum Toxin type A (BTX‐A) injection
Trial: 20479765
Drug: Tesofensine (TE)
RxNorm normalized name: ethanol
DrugBank: Tesofensine (DB06156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tesofensine (TE) 2.0 mg daily for 7 days followed by 1.0 mg daily for 7 days
Trial: 12028165
Drug: Oxybutynin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin group (2.5 mg daily to 5 mg three times a day)
Trial: 9607264
Drug: Fluoxetine 60
RxNorm normalized name: fluoxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine 60 mg once daily with diet
Trial: 7899538
Drug: Danazol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (200 mg bid)
Trial: 2223370
Drug: morphine 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: morphine 0.1 mg kg‐1
Trial: 2223370
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of morphine and alfentanil
Trial: 31752751
Drug: 12-week intervention
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week intervention (weekly emails and social media posts)
Trial: 25931799
Drug: Sevoflurane for
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane for inhalation anesthesia (I group)
Trial: 25931799
Drug: Propofol for
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol for total intravenous anesthesia (T group)
Trial: 23663213
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (community program)
Trial: 9697378
Drug: 2% pilocarpine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% pilocarpine four times daily
Trial: 1551720
Drug: sucralfate 1
RxNorm normalized name: sucralfate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sucralfate 1 g four times a day
Trial: 4002788
Drug: muzolimine 20
RxNorm normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine 20 mg
Trial: 4002788
Drug: muzolimine 40
RxNorm normalized name: Muzolimine
DrugBank: Muzolimine (DB13801)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: muzolimine 40 mg
Trial: 24904116
Drug: Treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen B
Trial: 24904116
Drug: Treatment regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment regimen C